BACKGROUND: To investigate the presence of T follicular helper (TFH) cells and their associated molecules in myasthenia gravis (MG) patients with thymoma. METHODS: TFH cells are detected in thymus around the thymoma region of 50 patients and atrophic thymus in 10 patients as control. The percentage of TFH cells among CD4(+) T cells and the expression level of surface markers CXC chemokine receptor 5 (CXCR5), inducible co-stimulator (ICOS), programmed cell death 1 and the cytoplasmic marker B cell lymphoma 6 (Bcl-6) were analyzed by immunohistochemistry (IHC) staining, immunofluorescence (IF) and western blotting (WB). RESULTS: Higher percentage of thymic TFH cells was found in MG patients with thymoma compared with both thymoma patients without MG and control group. The expression levels of the four markers in thymoma of MG patients were significantly higher than thymoma patients without MG and control group. No significant difference was found in the levels of programmed cell death 1 (PD-1) and Bcl-6 between thymoma patients without MG and the control, while the levels of CXCR5 and ICOS in thymoma patients without MG were higher than control group. CONCLUSIONS: These results suggested thymic TFH cells might involve in the pathogenesis of MG with thymoma. However, it needs further study to test if the inhibition of the function of TFH cells could effectively alleviate the severity of MG.
BACKGROUND: To investigate the presence of T follicular helper (TFH) cells and their associated molecules in myasthenia gravis (MG) patients with thymoma. METHODS: TFH cells are detected in thymus around the thymoma region of 50 patients and atrophic thymus in 10 patients as control. The percentage of TFH cells among CD4(+) T cells and the expression level of surface markers CXC chemokine receptor 5 (CXCR5), inducible co-stimulator (ICOS), programmed cell death 1 and the cytoplasmic marker B cell lymphoma 6 (Bcl-6) were analyzed by immunohistochemistry (IHC) staining, immunofluorescence (IF) and western blotting (WB). RESULTS: Higher percentage of thymic TFH cells was found in MGpatients with thymoma compared with both thymomapatients without MG and control group. The expression levels of the four markers in thymoma of MGpatients were significantly higher than thymomapatients without MG and control group. No significant difference was found in the levels of programmed cell death 1 (PD-1) and Bcl-6 between thymomapatients without MG and the control, while the levels of CXCR5 and ICOS in thymomapatients without MG were higher than control group. CONCLUSIONS: These results suggested thymic TFH cells might involve in the pathogenesis of MG with thymoma. However, it needs further study to test if the inhibition of the function of TFH cells could effectively alleviate the severity of MG.
Entities:
Keywords:
Myasthenia gravis (MG); T follicular helper cells (TFH cells); program death 1 (PD-1); thymoma
Authors: M Klein; F Heidenreich; F Madjlessi; A Granetzny; H P Dauben; H D Schulte; E Gams Journal: Thorac Cardiovasc Surg Date: 1999-06 Impact factor: 1.827
Authors: José María Remes-Troche; José Francisco Téllez-Zenteno; Bruno Estañol; Juan Garduño-Espinoza; Guillermo García-Ramos Journal: Arch Med Res Date: 2002 Nov-Dec Impact factor: 2.235
Authors: John S Yi; Jeffrey T Guptill; Panos Stathopoulos; Richard J Nowak; Kevin C O'Connor Journal: Muscle Nerve Date: 2017-09-30 Impact factor: 3.217
Authors: Bettina Schreiner; Burkhard Becher; Florian Ingelfinger; Sinduya Krishnarajah; Michael Kramer; Sebastian G Utz; Edoardo Galli; Mirjam Lutz; Pascale Zwicky; Ayse U Akarca; Nicole Puertas Jurado; Can Ulutekin; David Bamert; Corinne C Widmer; Luca Piccoli; Federica Sallusto; Nicolás G Núñez; Teresa Marafioti; Didier Schneiter; Isabelle Opitz; Antonio Lanzavecchia; Hans H Jung; Donatella De Feo; Sarah Mundt Journal: Acta Neuropathol Date: 2021-03-28 Impact factor: 17.088
Authors: A Uzawa; S Kuwabara; S Suzuki; T Imai; H Murai; Y Ozawa; M Yasuda; Y Nagane; K Utsugisawa Journal: Clin Exp Immunol Date: 2020-12-03 Impact factor: 5.732